Table 3.

Markov model describing transitions of liver fibrosis (progression or regression) (n = 1183).

	Fibrosis progression (aOR, 95% CI)	Fibrosis regression (aOR, 95% CI)
Age >50 years (yes vs. no)	0.99 (0.95–1.03)	0.99 (0.95–1.02)
Males (yes vs. no)	0.87 (0.36–2.09)	0.32 (0.14–0.75)
Overweight (yes vs. no)	1.12 (1.04–1.21)	1.00 (0.90–1.11)
Weight gain (yes vs. no)	3.11 (1.59–6.08)	0.30 (0.10–0.84)
Years since HIV diagnosis >10 years (yes vs. no)	1.09 (0.40–2.95)	1.19 (0.43–3.33)
Nadir CD4+ cell count <200 cell/μl (yes vs. no)	1.03 (0.53–2.03)	0.78 (0.35–1.74)
HBV coinfection (yes vs. no)	1.79 (0.52–6.20)	0.30 (0.04–2.51)
HCV coinfection (yes vs. no)	1.65 (0.79–3.44)	0.63 (0.29–1.39)
Current exposure to INSTI (yes vs. no)	0.61 (0.26–1.45)	0.73 (0.34–1.58)
Current exposure to protease inhibitors (yes vs. no)	0.85 (0.35–2.06)	1.17 (0.55–2.50)
Current exposure to NNRTI (yes vs. no)	0.41 (0.15–1.11)	0.99 (0.45–2.18)
Current exposure to TAF (yes vs. no)	1.11 (0.55–2.26)	0.96 (0.43–2.14)

Odds ratios (OR) and 95% confidence intervals (CI) are shown for each variable analyzed.

aOR, adjusted odds ration; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; INSTI, integrase strand transfer inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitors; TAF, tenofovir alafenamide.